Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Zhejiang University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of autologous peripheral hematopoietic stem cell transplantation in ischemic stroke.
Stroke is among the main causes of mortality and disability of elderly population which still lack of efficient therapy. Stem sell transplantation provides a functional improvement after cerebral ischemia in rat models. Our study will recruit 40 ischemic stroke patients which will be divided into 2 groups (20 patients each): treatment group and control group. The former will be implanted with peripheral blood stem cell through anterior cerebral artery or middle cerebral artery (determined by the section of infarction) and receive convention stroke therapy. The latter only receive convention stroke therapy. The investigators expect that transplantation of the peripheral hematopoietic stem cell is safe and efficient to neurological recovery.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| cell transplantation | Experimental | The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy. |
|
| Convention therapy | No Intervention | The control group just receive drug therapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| autologous hematopoiesis stem cell transplantation | Procedure | Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in NIH-stroke scale (NIHSS) at 12 months | 1,3,6,12 months after cell transplantation |
| Measure | Description | Time Frame |
|---|---|---|
| Barthel index | 1,3,6,12 months after cell transplantation | |
| perfusion magnetic resonance imaging scan | 1,3,6,12 months after cell transplantation | |
| Modified Rankin Scale(mRS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yaguo Li, master | Contact | 0086-0571-87987373 | 5103 | tjqlyg@163.com |
| Yumiao Zhou, master | Contact | 0086-0571-87987373 | 5094 | zlf859@yahoo.com.cn |
| Name | Affiliation | Role |
|---|---|---|
| Yaguo Li, master | Zhejiang Hospital | Study Director |
| Yumiao Zhou, master | Zhejiang Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yaguo Li | Recruiting | Hangzhou | Zhejiang | 310013 | China |
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001241 | Aspirin |
| D014859 | Warfarin |
| D000069059 | Atorvastatin |
| D000077553 | Edaravone |
| ID | Term |
|---|---|
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Aspirin | Drug | aspirin 100mg,qd,po(patients with no fibrillation atrial) |
|
| Warfarin | Drug | warfarin 2~6mg,qd,po(patients with fibrillation atrial); |
|
| Atorvastatin | Drug | atorvastatin 20mg,qd,po |
|
| Edaravone | Drug | edaravone 30mg,bid,ivgtt. |
|
| Aspirin | Drug | aspirin 100mg,qd,po(patients with no fibrillation atrial) |
|
| Warfarin | Drug | warfarin 2~6mg,qd,po(patients with fibrillation atrial) |
|
| Atorvastatin | Drug | atorvastatin 20mg,qd,po |
|
| Edaravone | Drug | edaravone 30mg,bid,ivgtt |
|
| 3,6,12 months after cell transplantation |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006841 |
| Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D015110 | 4-Hydroxycoumarins |
| D003374 | Coumarins |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D000983 | Antipyrine |
| D047069 | Pyrazolones |
| D011720 | Pyrazoles |